TED is a rare autoimmune disorder in which the muscles and fatty tissues behind the eye become inflamed, causing the eyes to ...

Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease (TED) ...

Topline results have been announced from a Phase 2/3 trial assessing linsitinib for the treatment of active, moderate to ...

Modifiable risk factors for thyroid eye disease include smoking habits and patient endocrine status. Avoid treating patients with active TED with radioactive iodine ablation. KOLOA, Hawaii ...

Patients with obesity have more orbital fat expansion, which, in the setting of thyroid eye disease, can lead to more severe proptosis, according to research published in BMC Ophthalmology . The study ...

Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release ...

In 2022, the total prevalent cases of thyroid eye disease (TED) in the United States were approximately 1,012,000, making up about 42% of the total 7MM population. . Germany accounted for around ...

TED most often occurs in conjunction with Graves disease but can occur in people without Graves disease who have had hyperthyroidism, hypothyroidism, or other thyroid conditions. 7 As a result, signs ...

Linsitinib is an oral small molecule that inhibits the activity of insulin-like growth factor-1 receptor (IGF-1R). It is believed that inhibition of IGF-1R may help reduce orbital inflammation and ...